Kelli Lehto, Associate Professor of Neuropsychiatric Genomics, University of Tartu

Value of the Information & Strength of the Argument

The talk provides valuable insights into the practical applications of genomic data in psychiatric care, using the Estonian Biobank as a case study. The argumentation is solid: she presents concrete examples and data from her group’s studies, such as the early vs. late onset depression findings and the predictive power of polygenic scores for clinical outcomes. The value lies in demonstrating how biobank-scale data combined with fine-grained phenotyping can reveal subtype-specific genetic associations and potentially guide clinical decisions (e.g., identifying patients at high risk of bipolar disorder or suicide). The logical flow is clear: from resource description to methodological innovations (symptom-level anal), and finally to translational attempts. She also honestly acknowledges limitations, such as the modest variance explained by polygenic scores and the need for better phenotypic accuracy. This balanced approach strengthens the credibility of the presented research.

Scientific Rigor, Source Quality, Title Accuracy

The presenter cites key resources such as the Estonian Biobank, the Psychiatric Genomics Consortium, and the UK Biobank (for questionnaire design). She references the latest flagship paper on the Estonian Biobank, though no explicit URL is provided in the description. The methods are aligned with international standards (e.g., harmonization with Nordic biobanks, polygenic score calculations). The title is accurate, as it directly identifies the speaker and her professional position, matching the content of a research presentation. No comments were available for analysis, so public reception cannot be assessed. Overall, scientific rigor is high, with transparent methodology and open acknowledgment of caveats, although detailed citations are not provided in the talk itself.

The title accurately reflects the speaker and her role, and the content aligns with her area of expertise.

8/10

High-quality presentation by an associate professor in psychiatric genomics, drawing on large biobank data and established consortia, with transparent methods and limitations acknowledged.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction to the talk and speaker's research team focus areas
• 01:30Overview of the Estonian Biobank: >200,000 participants, ~20% of adult population, genotyped, linked to EHR
• 03:00Prevalence of psychiatric diagnoses in the biobank (>50% have a psychiatric diagnosis) and trends in ADHD diagnoses
• 05:00Genomic findings: early vs. late onset depression show different genetic associations and outcomes
• 07:30Large-scale mental health questionnaire (86,000 responses) and its value for symptom-level analyses
• 09:30ADHD symptom genetics: distinct findings for inattention vs. hyperactivity (FoxP2 gene)
• 12:00Using polygenic scores to predict depression-to-bipolar transition over 17 years of follow-up
• 14:30Polygenic scores for suicide risk and treatment-resistant depression
• 17:00Metabolomics associations with depressive symptoms and the influence of BMI
• 20:00Q&A discussion on variance explained and limitations of polygenic scores

• Estonian Biobank flagship paper — Referenced as a QR code for detailed information about the biobank
• Psychiatric Genomics Consortium — Source for large-scale GWAS and heritability estimates
• UK Biobank mental health questionnaire — Model for the Estonian questionnaire design
• Nordic biobank collaboration — Cross-biobank harmonization efforts, e.g., depression subtypes